Pharma Pulse 6/18/24: ADHD Opportunity Assessment and Forecasts, Ensuring Ethical GLP-1 Practices & more

Ensuring Ethical Practices in Light of Potential Misuse

In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, talks about what steps companies developing weight-loss medications should take to ensure responsible and ethical practices.

Drug Shortages in Community Oncology: Ensuring Access to Chemotherapy

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

Finding the Right Partner for Your Clinical Trial

Learn more about why CROs are advocating for operational shifts necessary to support the adoption of innovative solutions to capture data and the significance of partnering with a CRO who can support initiatives throughout the entire clinical trial continuum using innovative data capture methods and their knowledge to facilitate global submissions.

OpenAI Expands Healthcare Push With Color Health’s Cancer Copilot

Color Health has developed an AI assistant using OpenAI’s GPT-4o model to help doctors screen and treat cancer patients.

Attention Deficit Hyperactivity Disorder (ADHD) Opportunity Assessment and Forecasts 2022-2024 & 2032

The "Attention Deficit Hyperactivity Disorder (ADHD): Opportunity Assessment and Forecast 2022-2032" report has been added to ResearchAndMarkets.com's offering.

The ADHD therapeutics market, valued at $11.9 billion in the 2022 baseline year, is expected to encounter a negative compound annual growth rate (CAGR) of 0.9%, ultimately reaching an estimated $10.9 billion by 2032.

@health on Threads

Rest days are CRUCIAL to your overall health goals. Give yourself a break!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs